TY - JOUR
T1 - Advances in the treatment of primary brain tumors
T2 - Dawn of a new era?
AU - Gilbert, Mark R.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2006/1
Y1 - 2006/1
N2 - The prognosis for patients with malignant primary brain tumors has been poor, and until recently, there was little evidence that chemotherapy was beneficial. The publication of the phase III trial comparing the combination of temozolomide with external beam radiation therapy with radiation therapy alone demonstrated a clear survival benefit for the combination regimen. These results, along with improvements in clinical trial design and outcome assessment, advances in our understanding of glioma tumor biology, and recognition of critical drug-drug interactions, have provided a foundation for developing better treatments for these cancers.
AB - The prognosis for patients with malignant primary brain tumors has been poor, and until recently, there was little evidence that chemotherapy was beneficial. The publication of the phase III trial comparing the combination of temozolomide with external beam radiation therapy with radiation therapy alone demonstrated a clear survival benefit for the combination regimen. These results, along with improvements in clinical trial design and outcome assessment, advances in our understanding of glioma tumor biology, and recognition of critical drug-drug interactions, have provided a foundation for developing better treatments for these cancers.
UR - http://www.scopus.com/inward/record.url?scp=31544439597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=31544439597&partnerID=8YFLogxK
U2 - 10.1007/s11912-006-0008-6
DO - 10.1007/s11912-006-0008-6
M3 - Review article
C2 - 16464402
AN - SCOPUS:31544439597
SN - 1523-3790
VL - 8
SP - 45
EP - 49
JO - Current oncology reports
JF - Current oncology reports
IS - 1
ER -